Actively Recruiting

Phase 1
Age: 18Years +
All Genders
NCT07401680

Fecal Microbiota Transplantation in an Expanded Ulcerative Colitis Population

Led by University of Alberta · Updated on 2026-05-08

85

Participants Needed

2

Research Sites

143 weeks

Total Duration

On this page

Sponsors

U

University of Alberta

Lead Sponsor

U

University of Calgary

Collaborating Sponsor

AI-Summary

What this Trial Is About

This is a multi-centre, randomised controlled trial comparing fecal microbiota transplantation to placebo in an expanded ulcerative colitis population: a feasibility study (FRONTIER-UC) to determine whether a full-scale randomized controlled trial (RCT) to investigate fecal microbiota transplantation (FMT) in ulcerative colitis (UC) is feasible.

CONDITIONS

Official Title

Fecal Microbiota Transplantation in an Expanded Ulcerative Colitis Population

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • 18 years of age or older
  • Able to provide informed consent
  • Established ulcerative colitis diagnosis through standard endoscopic and histologic criteria
  • Active ulcerative colitis
  • Use of effective contraception method for women of childbearing potential for at least 4 weeks prior to receiving study treatment and for the duration of the trial
  • Willing and able to comply with all required study procedures
Not Eligible

You will not qualify if you...

  • Severe ulcerative colitis requiring hospitalization
  • Crohn's disease or indeterminate colitis
  • Irritable bowel syndrome
  • Intestinal infection within 4 weeks of enrollment
  • Evidence of toxic megacolon or gastrointestinal perforation on imaging
  • Planned colectomy
  • Abdominal surgery within 60 days of enrollment
  • Neutropenia with absolute neutrophil count <0.5 x 10^9/L
  • Peripheral white blood cell count > 35.0 x 10^9/L and fever (>38C)
  • Planned or actively taking another investigational product
  • Uncontrolled medical conditions such as psychiatric disorders or substance abuse
  • Severe underlying disease such that the patient is not expected to survive for at least 30 days
  • Pregnancy or breastfeeding
  • Unwilling to discontinue non-dietary probiotic
  • Antibiotic use 30 days prior to enrollment or anticipated need for systemic antibiotic use during study
  • FMT for any reason within 6 months of enrollment
  • Investigator's judgement that enrolment is not in the best interest of the patient

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

University of Calgary

Calgary, Alberta, Canada, T2N-1N4

Not Yet Recruiting

2

University of Alberta

Edmonton, Alberta, Canada, T6G2R3

Actively Recruiting

Loading map...

Research Team

D

Dina Kao, MD,FRCPC

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

4

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here